Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $380000.0.

  • UroGen Pharma's Long-Term Investments fell 9181.21% to $380000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $380000.0, marking a year-over-year decrease of 9181.21%. This contributed to the annual value of $5.0 million for FY2024, which is 1155.04% up from last year.
  • Latest data reveals that UroGen Pharma reported Long-Term Investments of $380000.0 as of Q3 2025, which was down 9181.21% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Long-Term Investments ranged from a high of $10.2 million in Q1 2023 and a low of $203000.0 during Q2 2024
  • In the last 5 years, UroGen Pharma's Long-Term Investments had a median value of $4.1 million in 2021 and averaged $3.4 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first tumbled by 9944.44% in 2021, then surged by 281793.72% in 2023.
  • Quarter analysis of 5 years shows UroGen Pharma's Long-Term Investments stood at $675000.0 in 2021, then crashed by 66.96% to $223000.0 in 2022, then skyrocketed by 1918.83% to $4.5 million in 2023, then increased by 11.55% to $5.0 million in 2024, then plummeted by 92.43% to $380000.0 in 2025.
  • Its Long-Term Investments stands at $380000.0 for Q3 2025, versus $4.6 million for Q2 2025 and $4.5 million for Q1 2025.